Camurus and Braeburn Pharmaceuticals Announce Positive Top-line Results from Phase 3 Safety Study of CAM2038
– New data support long-term safetyand efficacy ofweekly andmonthly subcutaneous buprenorphine depots in patients with opioid use disorder Camurus (NASDAQ STO: CAMX) and Braeburn Pharmaceuticals…